ICMR-Developed SHetA2 Oral Drug Targets HPV-Related Cervical Precancerous Lesions

Key facts

• SHetA2 is an investigational oral therapy designed to treat precancerous cervical lesions caused by HPV, not prevent the initial infection.
• The drug was developed by the Indian Council of Medical Research (ICMR) and licensed to Emcure Pharmaceuticals for further development.
• It works by targeting and destroying HPV-infected cells while potentially sparing healthy tissue.
• Current treatment for high-grade cervical precancer involves surgical procedures such as Loop Electrosurgical Excision Procedure (LEEP) or conisation.
• SHetA2 could offer a non-surgical, tissue-preserving alternative if future clinical trials confirm its safety and effectiveness.
• The drug is still several years away from routine clinical use, requiring larger human trials that could take up to five years.
• Challenges to availability include pricing under India's Drugs Prices Control Order (DPCO), manufacturing at scale, and equitable distribution across urban and rural India.
• Experts stress that HPV vaccination and regular screening (e.g., Pap smears) remain the most effective prevention strategies against cervical cancer.